Alopecia areata (AA) is a form of non-scarring hair loss. Physiologically, it is a complex T-cell-mediated autoimmune condition, where hair follicles prematurely skip from the growing anagen phase to the resting telogen phase, resulting in hair loss1. It affects people of all ages, including children and adolescents2.
This Alopecia areata Learning Zone aims to educate healthcare professionals (HCP) on:
- Unmet medical needs for AA, such as more effective treatments suitable for long-term use
- Timely AA management by highlighting the lived burden of AA
- Treatment planning for adult patients with severe AA, by describing the pathophysiology underpinning autoimmunity in AA, and the emerging role of treatment with janus kinase (JAK) inhibitors
Short, informative videos complement the written content. Watch Lynn Wilks, a patient with AA, discuss her lived experience of AA, and her honest messages for clinicians for management of this condition.
- Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019;98:74–85.
- Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257–265.
are looking at
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors Pfizer, who have reviewed the content only for scientific accuracy. EPG Health received funding from the sponsor in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content.